{"id":"W4388738295","doi":"10.1097/01.hs9.0000936192.21618.f2","title":"P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Janssen Scientific Affairs; Centre Hospitalier Universitaire de Toulouse; Universitätsklinikum Hamburg-Eppendorf; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Texas MD Anderson Cancer Center; Ankara Universitesi; University of Oxford; Université de Lille; Cancer Research Institute","keywords":"Medicine; Lenalidomide; Daratumumab; Quality of life (healthcare); Internal medicine; Multiple myeloma; Population; Dexamethasone; Subgroup analysis; Randomized controlled trial; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003723992,0.001105351,0.003071529,0.0004656065,0.0003340623,0.001203427,0.0007316404,0.0008417392,0.002140135],"category_scores_gemma":[0.004193818,0.0002950637,0.008325954,0.0006040936,0.0004160092,0.0005814113,0.000724055,0.001455093,0.0001981468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005890182,"about_ca_system_score_gemma":0.0007492661,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009087382,"about_ca_topic_score_gemma":0.00269476,"domain_scores_codex":[0.9984233,0.0007797363,0.0002540425,0.0002718912,0.0001251756,0.0001458564],"domain_scores_gemma":[0.9982462,0.000598706,0.0005645372,0.0002580005,0.00007945598,0.0002531117],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8312647,0.000779928,0.07047834,0.002534977,0.06089474,0.0002490242,0.0001826635,0.001328042,0.002681046,0.0002925313,0.002308046,0.027006],"study_design_scores_gemma":[0.4289912,0.05514879,0.3757593,0.001129308,0.1203499,0.0009247546,0.000425633,0.00537781,0.001925134,0.003035468,0.006729048,0.0002035402],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9757876,0.01824813,0.0005084758,0.0006746415,0.0002255347,0.0007668665,0.00265637,0.00003053218,0.001101888],"genre_scores_gemma":[0.9951636,0.001201128,0.000311911,0.0003111881,0.0001747304,0.0007321368,0.001697475,0.000007885896,0.0003999289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003723992,"threshold_uncertainty_score":0.01969463,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04459092877840427,"score_gpt":0.3177322132499836,"score_spread":0.2731412844715793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}